Affinity Asset Advisors, LLC Cytom X Therapeutics, Inc. Transaction History

Affinity Asset Advisors, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$3.87 - $7.39 $483,750 - $923,750	-125,000 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$4.32 - $6.43 $216,000 - $321,500	50,000 Added 66.67%	125,000 $636,000
Q2 2021 Aug 13, 2021	BUY	$6.33 - $9.91 $158,250 - $247,750	25,000 Added 50.0%	75,000 $475,000
Q1 2021 May 14, 2021	BUY	$6.6 - $9.0 $330,000 - $450,000	50,000 New	50,000 $387,000

50.2M

22.3K

22.9K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $79.1M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.